Unlock instant, AI-driven research and patent intelligence for your innovation.

Compositions as adjuvants to improve immune responses to vaccines and methods of use

A composition and compound technology, applied in the direction of antibodies, etc., can solve problems such as ineffectiveness

Inactive Publication Date: 2007-09-12
TELOS PHARMA
View PDF21 Cites 20 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A disadvantage of such adjuvants is that they are relatively ineffective at stimulating cell-mediated immune responses and produce a largely Th2-biased immune response

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions as adjuvants to improve immune responses to vaccines and methods of use
  • Compositions as adjuvants to improve immune responses to vaccines and methods of use
  • Compositions as adjuvants to improve immune responses to vaccines and methods of use

Examples

Experimental program
Comparison scheme
Effect test

Embodiment I

[0137] Purification of anti-TIM-1 antibody

[0138] Hybridomas secreting mouse anti-human TIM-1 antibody or rat anti-mouse TIM-1 antibody were initially cultured in cell culture flasks and subsequently transferred to Bioperm cell culture reactors. Every 48 hours, culture supernatants containing secreted antibodies were harvested, clarified, and stored at 4°C. The collected supernatants were pooled and anti-TIM-1 antibodies were purified from the supernatants by protein G Sepharose affinity chromatography and eluted from the column using glycine pH 2.5-3.5. The eluate was pH neutralized and dialyzed against phosphate buffered saline (PBS). Purified antibodies were stored at -80°C until further use.

Embodiment II

[0140] Construction of DNA vectors for mouse and human TIM-1 / Fc fusion protein expression

[0141] A shuttle plasmid vector (pTPL-1) for cloning TIM-1 / Fc fusion protein gene fragment was designed and constructed. The base vector pTPL-1 carries bacterial and eukaryotic resistance genes and a multiple cloning site flanked by CMV enhancers and β-globin polyadenylation sites (see also Figure 18, TIM-3 fusion). Mouse non-lytic IgG2a / Fc fragments (hinge, CH2 and CH3 domains) were generated by oligonucleotide-directed mutagenesis to replace the C1q binding motif and inactivate the FcγR1 binding site (Zheng et al., J . Immunol. 154:5590-5600 (1995)).

[0142] An Fc region, which may be part of an agent of the invention, may be "lytic" or "non-lytic". Non-lytic Fc regions generally lack the high affinity Fc receptor binding site and the C'Iq binding site. The high affinity Fc receptor binding site of murine IgG Fc includes a Leu residue at position 235 of IgG Fc. Thus, by mutating ...

Embodiment III

[0146] Transient expression of TIM / Fc fusion protein in 293 cells

[0147] To test the functionality of the resulting expression vectors, transient transfections were performed in 293 cells. Briefly, 80-90% confluent cells in serum-free growth medium (293-SFMII; InvitroGen, Carlsbad, CA) were transfected using the Lipofectamine 2000 system according to the manufacturer's instructions (InvitroGen, Carlsbad, CA). of 293 cells. Routinely, use 1 μg plasmid DNA / 10 5 cell. One day after transfection, the growth medium was replaced with fresh medium and the cells were cultured for a maximum of 7 days. Cell culture supernatants were clarified by centrifugation and TIM-1 / Fc or TIM-3 / Fc fusion proteins were purified by protein G sepharose affinity chromatography. After low pH elution from protein G beads, the purified protein was dialyzed against PBS and stored at -80°C. Proteins produced were analyzed for identity, purity and integrity by sodium dodecyl sulfate-polyacryla...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides compositions containing an antigen and a TIM targeting molecule. The invention additionally provides a TIM targeting molecule conjugate, for example, a TIM targeting molecule targeted to a therapeutic or diagnostic moiety. The invention additionally provides methods of using such compositions. In one embodiment, the invention provides a method of stimulating an immune response in an individual by administering a composition comprising an antigen and a TIM targeting molecule in a pharmaceutically acceptable carrier. In another embodiment, the invention provides a method of stimulating an immune response in an individual by administering an antigen and a TIM targeting molecule, which can be administered together in a single composition or separately.

Description

Background of the invention [0001] The body's defense against microorganisms is mediated by early responses of the innate immune system and late responses of the adaptive immune system. Innate immunity involves mechanisms that recognize structures that, for example, are characteristic of microbial pathogens but are absent on mammalian cells. Examples of such structures include bacterial lipopolysaccharide (LPS), viral double-stranded RNA, and unmethylated CpG DNA nucleotides. Effector cells of the innate immune response include neutrophils, macrophages and natural killer cells (NK cells). In addition to innate immunity, vertebrates, including mammals, possess evolved immunological defense mechanisms that are stimulated by exposure to infectious agents and increase in magnitude and potency after each successive exposure to a specific antigen. Due to its ability to adapt to specific infection or antigenic insult, this immune defense mechanism has been described as acquired imm...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395A61K39/40
Inventor W·索霍E·R·詹森T·莫尔D·J·卡洛B·K·赫尔米奇S·叶J·塔特
Owner TELOS PHARMA